Announcements Trials
Browse Landscape

Status

Approved for marketing 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 35Expanded_access 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Small Cell Lung Carcinoma 1Lung Neoplasms 1

Interventions

3-Iodobenzylguanidine 9Amifampridine 6nilotinib 5Magnetic Resonance Spectroscopy 5Cyclophosphamide 5trametinib 4pembrolizumab 4gallium 68 PSMA-11 4fludarabine 4elotuzumab 4dabrafenib 4Nivolumab 4Bortezomib 4Afatinib 4venetoclax 3regorafenib 3midostaurin 3fludarabine phosphate 3TIC10 compound 3Sunitinib 3Prednisone 3Lenalidomide 3Ipilimumab 3Everolimus 3Dexamethasone 3Crizotinib 3Capecitabine 3Axitinib 3Alpelisib 3Abiraterone Acetate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Expanded_access × trilaciclib × Clear all
NCT04504513 2021-03-19

Expanded Access to Trilaciclib for Patients Receiving Chemotherapy for Small Cell Lung Cancer

G1 Therapeutics, Inc.

Approved for marketing
Thoracic

Lung Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡